In the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease), and EMPEROR (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure) trials, it was shown that SGLT2 inhibitors can decrease the risk of progression of heart failure and chronic kidney disease (CKD) in people with and without diabetes [11,12,13,14]. Here, SLC5A2 is linked to chronic kidney disease.